About Alpex Pharma
Alpex Pharma is a pharmaceutical company located in Mezzovico, near Lugano, Switzerland, specializing in R&D and production of effervescent and fast melt tabaims to let.On March 28th, 2022, Alpex Pharma merged with Alpen Group.
Missing: Alpex Pharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Alpex Pharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Alpex Pharma Patents
Alpex Pharma has filed 1 patent.
Kidney diseases, Prodrugs, Hepatotoxins, Fluoroarenes, Carboxylic acids
Kidney diseases, Prodrugs, Hepatotoxins, Fluoroarenes, Carboxylic acids
Latest Alpex Pharma News
Nov 19, 2022
People are embracing a more sedentary lifestyle as the middle class expands and urbanisation accelerates. Obesity rates and occurrences of diseases like diabetes are rising as a result of this. According to the World Health Organization, the prevalence of chronic disease will rise by 57% by 2020. GlobalData epidemiologists predict that by 2021, India will have 75.26 million diagnosed prevalent cases of type 2 diabetes and 26,000 diagnosed incident cases of endometrial cancer, with 91.72 million and 32,000 cases, respectively, by 2028. According to the American Cancer Society, in 2021, there will be 1.9 million new cancer diagnoses and 608,570 cancer deaths in the United States. According to a report published by Frontiers In Public Health, chronic noncommunicable diseases account for about 80% of the mortality among adults aged 60 in China, with ischemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), and type 2 diabetes being the most common. Smoking, alcohol usage, sedentary activity, and poor nutritional intake are all significant contributors to these diseases. Oral drug delivery systems are expected to become more popular as the prevalence of chronic diseases rises around the world. According to the World Population Prospects: the 2019 Revision, by 2050, one out of every six people on the planet will be over the age of 65 (16%), from one out of every eleven in 2019 (9%). One in every four people in Europe and North America could be 65 or older by 2050. In 2018, people aged 65 and older outnumbered kids under the age of five for the first time in history on a global level. From 143 million in 2019 to 426 million in 2050, the number of people aged 80 and up is expected to treble. Eastern and South-Eastern Asia’s population aged 65 and above nearly doubled from 6% in 1990 to 11% in 2019, while Latin America and the Caribbean’s population aged 65 and above nearly doubled from 5% in 1990 to 9% in 2019. The growing geriatric population around the world is also expected to propel market growth in the forecast period. Moreover, rising research and development and partnerships amongst market players will expand the growth of oral delivery globally. For instance, SWK Holdings Corporation announced the acquisition of Enteris BioPharma in August 2019. This acquisition will allow the company to broaden its product line and provide more advanced products to its clients. This will also allow the company to become a pioneer in the field of orally delivered peptide and small molecule therapies. Similarly, in September 2021, Bio-Thera Solutions signed an agreement with Intract, acquiring the licence to employ the oral delivery system with a single monoclonal antibody that will remain unnamed. Moreover, in November 2021, EsoCap completed private funding round, with existing and new investors participating. The funds will be utilised to further develop and industrialise EsoCap’s focused application technology, which will allow for the effective local therapy of esophageal illnesses. During the projected period, North America is anticipated to dominate the oral drug delivery market. During the forecast period, North America is expected to have a large market share. Technological advances, rising patent approvals, and research on the usage of nanotechnology for drug delivery in the region are expected to drive the market. For example, Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical firm researching oral drug delivery systems, got a US patent in March 2019. Furthermore, due to the rapid adoption of new drug delivery technologies and the presence of research centres developing innovative drug delivery systems in the country, the United States is expected to hold a significant share of the oral drug delivery systems market in North America during the forecast period. Market Segmentation:
Alpex Pharma Web Traffic
Alpex Pharma Rank
Alpex Pharma Frequently Asked Questions (FAQ)
When was Alpex Pharma founded?
Alpex Pharma was founded in 1988.
Where is Alpex Pharma's headquarters?
Alpex Pharma's headquarters is located at Via Cantonale, Mezzovico.
What is Alpex Pharma's latest funding round?
Alpex Pharma's latest funding round is Merger.
Who are the investors of Alpex Pharma?
Investors of Alpex Pharma include Alpen Group, BB Biotech Ventures, Signet Healthcare Partners and Bellevue Asset Management.
Who are Alpex Pharma's competitors?
Competitors of Alpex Pharma include Unither Pharmaceuticals, Kiadis Pharma, OcuCure Therapeutics, Evoke Pharma, ZARS and 13 more.
Compare Alpex Pharma to Competitors
greece vacation pharmaceutical company athens hotel naxos pharma travel tour
An R&D company focusing on technologies in imaging. Predictek analyzes functional brain images for the pharmaceutical industry, and is developing a new kind of multispectral imaging for use by eye care professionals.
OcuCure Therapeutics is an ophthalmic pharmaceutical company developing new drugs. The company's lead compound has been formulated as a topical eye drop for both Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). AMD and DR are leading causes of blindness in developed countries. Additionally, the lead compound has potential for use as a prophylactic. The presence of the therapeutic target has been validated in human AMD and DR tissues. This confirms the OcuCure approach for treating ocular angiogensis. The topical eye drop also has demonstrated the ability to cross human corneas in in vitro studies. When the eye drop was administered to animals, the lead compound penetrated all the way back to the retina at clinically significant concentrations without any toxic effects observed. By comparison, the currently available drugs for AMD are administered by a monthly injection into the eye.
Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.
Azur Pharma is a pharmaceutical company focused on the CNS, women's health and urology markets of the US.
Xanodyne Pharmaceuticalsis a speciality pharmaceutical company focused on products for women's health care and pain management.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.